Dr. Orfeu Flores is the founder and current CEO of STAB VIDA (2001). He holds a B.Sc. in Applied Chemistry (1992) from Universidade Nova de Lisboa – Portugal; a M.Sc. in Science and Technology Commercialization (1998) from Texas University – USA; and a Ph.D. in Biology/Molecular Genetics (2015) from Universidade Nova de Lisboa – Portugal. In 2001, he was awarded “Young Entrepreneur of the Year 2001” by the Portuguese Academy of Young Businessmen. He is also an expert for European Commission RTD H2020, being a member of several panels for project evaluation. Dr. Flores holds large experience in sequencing-methods (Sanger and NGS), bioinformatics and, more recently, in antibody production, modification and functionalization. In fact, STAB VIDA has been putting a strong R&D dedication to develop antibody-based nanoparticles towards diagnostics and therapeutic approaches for Alzheimer’s disease, having made considerable advances in short-time, with three papers published in high impact journals of which Dr. Flores is a co-author.
STAB VIDA, Investigação e Serviços em Ciências Biológicas (www.stabvida.com), established in 2001, is a Portuguese ISO9001:2008 certified biotech SME with 25 employees and a dedicated line of products and services for genetics, genomics and immunology (www.stabvida.com/en/services/2015-catalog). Its main R&D interests for commercialization are focused in point-of-care diagnostics and theragnostics (mainly for Alzheimer, Lyme and Cancer diseases), oligo synthesis, bioinformatics and nucleic acid sequencing, including next-generation sequencing (NGS), for the biotechnology and biomedical research and clinical community. Currently, STAB VIDA’s sales territory is mainly spread throughout Portugal, Spain, UK, Italy, South America (Brazil, Chile and Uruguay) and Africa (Angola and Nigeria), including a client portfolio of more than 20 clinical diagnostic laboratories/centers.
STAB VIDA’s team accounts with a vast know-how in the field of genetics, genomics, immunology and nanobiotechnology, and also has an extensive experience of participating and coordinating national and European projects (FP6, FP7 and H2020).
This project has received funding from the European Union´s Horizon 2020 research and innovation programme under grant agreement No 686009